Svoboda | Graniru | BBC Russia | Golosameriki | Facebook
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Current Developments in Glioblastoma Research and Therapy
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Current Developments in Glioblastoma Research and Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 20 December 2024 | Viewed by 3423

Special Issue Editor

Dr. Aleksandra Majchrzak-Celińska

E-Mail Website
Guest Editor
Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 60-806 Poznan, Poland
Interests: brain tumors; glioblastoma; epigenetics; pharmacoepigenetics; biomarkers; Wnt/β-catenin pathway; phytocompounds
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Glioblastoma remains one of the most aggressive and incurable malignancies. Even after the standard treatment, consisting of surgery, radiotherapy, and chemotherapy, tumor recurrence is only a matter of time and the prognosis for glioblastoma patients is still very poor. Therefore, rapid progress in developing a better understanding of glioblastoma pathogenesis and recurrence is needed and novel ways to improve patient outcomes are desperately required.

Fortunately, glioblastoma research is thriving, and new approaches towards the more precise diagnosis and effective therapy of this deadly disease are constantly being evaluated. The implementation of combinatorial therapies, immunotherapy, and nanomedicine are several of the examples of strategies tested in order to surpass the current obstacles in glioblastoma treatment.

The aim of this Special Issue is to collect the most recent discoveries regarding glioblastoma research, ranging from molecular mechanisms to therapeutic approaches. All advancements in characterizing GBM pathogenesis, including genomic, epigenomic, transcriptomic, and proteomic analyses of GBM cells, are of interest in this Special Issue. Moreover, we welcome the evaluation of innovative therapeutic agents and new treatment approaches.

We invite authors to submit original preclinical, translational, and clinical works, as well as review articles regarding the above-mentioned cutting-edge topics, to this Special Issue of International Journal of Molecular Sciences.

We are looking forward to your contributions.

Dr. Aleksandra Majchrzak-Celińska
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diagnostic, prognostic and predictive biomarkers of glioblastoma
  • ways to target glioma stem cells
  • targeting glioblastoma-related signaling pathways
  • epigenetics of glioblastoma
  • treatment resistance mechanisms
  • novel treatment options for glioblastoma
  • combinatorial therapies
  • immunotherapy
  • nanotherapy
  • the application of CRISPR/Cas9 in glioma research
  • molecular testing of long-term glioblastoma survivors

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

19 pages, 10685 KiB  
Article
Evaluation of Microvascular Density in Glioblastomas in Relation to p53 and Ki67 Immunoexpression
by Tamás-Csaba Sipos, Attila Kövecsi, Lóránd Kocsis, Monica Nagy-Bota and Zsuzsánna Pap
Int. J. Mol. Sci. 2024, 25(12), 6810; https://doi.org/10.3390/ijms25126810 - 20 Jun 2024
Viewed by 538
Abstract
Glioblastoma is the most aggressive tumor in the central nervous system, with a survival rate of less than 15 months despite multimodal therapy. Tumor recurrence frequently occurs after removal. Tumoral angiogenesis, the formation of neovessels, has a positive impact on tumor progression and [...] Read more.
Glioblastoma is the most aggressive tumor in the central nervous system, with a survival rate of less than 15 months despite multimodal therapy. Tumor recurrence frequently occurs after removal. Tumoral angiogenesis, the formation of neovessels, has a positive impact on tumor progression and invasion, although there are controversial results in the specialized literature regarding its impact on survival. This study aims to correlate the immunoexpression of angiogenesis markers (CD34, CD105) with the proliferation index Ki67 and p53 in primary and secondary glioblastomas. This retrospective study included 54 patients diagnosed with glioblastoma at the Pathology Department of County Emergency Clinical Hospital Târgu Mureș. Microvascular density was determined using CD34 and CD105 antibodies, and the results were correlated with the immunoexpression of p53, IDH1, ATRX and Ki67. The number of neoformed blood vessels varied among cases, characterized by different shapes and calibers, with endothelial cells showing modified morphology and moderate to marked pleomorphism. Neovessels with a glomeruloid aspect, associated with intense positivity for CD34 or CD105 in endothelial cells, were observed, characteristic of glioblastomas. Mean microvascular density values were higher for the CD34 marker in all cases, though there were no statistically significant differences compared to CD105. Mutant IDH1 and ATRX glioblastomas, wild-type p53 glioblastomas, and those with a Ki67 index above 20% showed a more abundant microvascular density, with statistical correlations not reaching significance. This study highlighted a variety of percentage intervals of microvascular density in primary and secondary glioblastomas using immunohistochemical markers CD34 and CD105, respectively, with no statistically significant correlation between evaluated microvascular density and p53 or Ki67. Full article
(This article belongs to the Special Issue Current Developments in Glioblastoma Research and Therapy)
►▼ Show Figures

Figure 1

14 pages, 1652 KiB  
Article
Profiling of Tumor-Infiltrating Immune Cells and Their Impact on Survival in Glioblastoma Patients Undergoing Immunotherapy with Dendritic Cells
by Nataly Peres, Guilherme A. Lepski, Carla S. Fogolin, Gabriela C. M. Evangelista, Elizabeth A. Flatow, Jaqueline V. de Oliveira, Mariana P. Pinho, Patricia C. Bergami-Santos and José A. M. Barbuto
Int. J. Mol. Sci. 2024, 25(10), 5275; https://doi.org/10.3390/ijms25105275 - 12 May 2024
Viewed by 2271
Abstract
Glioblastomas (GBM) are the most common primary malignant brain tumors, comprising 2% of all cancers in adults. Their location and cellular and molecular heterogeneity, along with their highly infiltrative nature, make their treatment challenging. Recently, our research group reported promising results from a [...] Read more.
Glioblastomas (GBM) are the most common primary malignant brain tumors, comprising 2% of all cancers in adults. Their location and cellular and molecular heterogeneity, along with their highly infiltrative nature, make their treatment challenging. Recently, our research group reported promising results from a prospective phase II clinical trial involving allogeneic vaccination with dendritic cells (DCs). To date, six out of the thirty-seven reported cases remain alive without tumor recurrence. In this study, we focused on the characterization of infiltrating immune cells observed at the time of surgical resection. An analytical model employing a neural network-based predictive algorithm was used to ascertain the potential prognostic implications of immunological variables on patients’ overall survival. Counterintuitively, immune phenotyping of tumor-associated macrophages (TAMs) has revealed the extracellular marker PD-L1 to be a positive predictor of overall survival. In contrast, the elevated expression of CD86 within this cellular subset emerged as a negative prognostic indicator. Fundamentally, the neural network algorithm outlined here allows a prediction of the responsiveness of patients undergoing dendritic cell vaccination in terms of overall survival based on clinical parameters and the profile of infiltrated TAMs observed at the time of tumor excision. Full article
(This article belongs to the Special Issue Current Developments in Glioblastoma Research and Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop